Questioning the oncogenic role of ΔNp73α in different cell lines expressing p53 or not

Cancer Biology and Therapy

Volumn 5, Issue 7, 2006, Pages 794-803

  Marrazzo, Eleonora ^a,b   Marchini, Sergio ^a   Previdi, Sara ^a   Broggini, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Laboratory of Molecular Pharmacology   (Italy)

Author keywords

p53; Tumor biology; Np73

Indexed keywords

CISPLATIN; DOXORUBICIN; DOXYCYCLINE; ISOPROTEIN; LUCIFERASE; PROTEIN P53; PROTEIN P73; TETRACYCLINE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOLECULAR CLONING; ONCOGENE; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

EID: 33751187878     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.7.2753     Document Type: Article

References (34)

1. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000; 60:6788-93.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
3. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93.
4. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002; 14:86-91.
5. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90:809-19.
6. Moll UM, Slade N. p63 and p73: Roles in development and tumor formation. Mol Cancer Res 2004; 2:371-86.
7. Stirewalt DL, Clurman B, Appelbaum FR, Willman CL, Radich JP. p73 mutations and expression in adult de novo acute myelogenous leukemia. Leukemia 1999; 13:985-90.
8. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E, Koeffler HP. Loss of p73 gene expression in Leukemias/Lymphomas due to hypermethylation [In Process Citation]. Blood 1999; 94:1113-20.
9. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation [In Process Citation]. Cancer Res 1999; 59:3352-6.
10. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
11. Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JY. Structure, function and regulation of p63 and p73. Cell Death Differ 1999; 6:1146-53.
12. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: A newly identified isoform of human p73. Cancer Res 2002; 62:636-41.
13. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: Implications for tumorigenesis. J Biol Chem 2002; 277:14177-85.
14. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T, Nakagawara A. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 2002; 22:2575-85.
15. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J Exp Med 2002; 196:765-80.
16. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19:2122-37.
17. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2:605-15.
18. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000; 289:304-6.
19. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004; 10:6905-11.
20. Guan M, Chen Y. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score. J Clin Pathol 2005; 58:1175-9.
21. Ugur H, Sayan AE, Ozdamar SO, Kanpolat Y, Ozturk M. Expression of TAP73 and DeltaNP73 in malignant gliomas. Oncol Rep 2004; 11:1337-41.
22. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. Transdominant {Delta}TAp73 isoforms are frequently upregulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64:2449-60.
23. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9:246-51.
24. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003; 23:5540-55.
25. Marabese M, Marchini S, Sabatino MA, Polato F, Vikhanskaya F, Marrazzo E, Riccardi E, Scanziani E, Broggini M. Effects of inducible overexpression of DNp73[alpha] on cancer cell growth and response to treatment in vitro and in vivo. 2005; 12:805-14.
26. Kartasheva NN, Lenz-Bauer C, Hartmann O, Schafer H, Eilers M, Dobbelstein M. DeltaNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 2003; 22:8246-54.
27. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 2002; 21:4715-27.
28. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001; 8:1213-23.
29. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D, Benard J. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002; 160:631-9.
30. Haapajarvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF, Laiho M. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Exp Cell Res 1999; 248:272-9.
31. Moustakas A, Kardassis D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci USA 1998; 95:6733-8.
32. Biggs JR, Kudlow JE, Kraft AS. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 1996; 271:901-6.
33. Tanaka Y, Kameoka M, Itaya A, Ota K, Yoshihara K. Regulation of HSF1-responsive gene expression by N-terminal truncated form of p73alpha. Biochem Biophys Res Commun 2004; 317:865-72.
34. Lee AF, Ho DK, Zanassi P, Walsh GS, Kaplan DR, Miller FD. Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms. J Neurosci 2004; 24:9174-84.